Latest & greatest articles for lansoprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lansoprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lansoprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lansoprazole

1. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis (Full text)

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO).In this phase III, double-blind, multicentre study, patients with endoscopically confirmed EO were randomised 1:1 to receive vonoprazan 20 mg or lansoprazole 30 mg, once daily for up (...) to 8 weeks. The primary endpoint was EO healing rate at 8 weeks. The secondary endpoints were EO healing rates at 2 and 4 weeks. Safety endpoints included treatment-emergent adverse events (TEAEs).In the vonoprazan (n=238) and lansoprazole (n=230) arms, 8-week EO healing rates were 92.4% and 91.3%, respectively (difference 1.1% (95% CI -3.822% to 6.087%)). The respective 2-week EO healing rates were 75.0% and 67.8% (difference 7.2% (95% CI -1.054% to 15.371%)), and the respective 4-week EO healing

2019 EvidenceUpdates PubMed abstract

2. Lansoprazole

Lansoprazole Top results for lansoprazole - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lansoprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study (Full text)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use.A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter (...) , single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence. The patients received vonoprazan (10 mg or 20 mg) or lansoprazole 15 mg once daily. For DB, non-inferiority of the proportion of patients with recurrent PU within 24 weeks was analysed by Farrington and Manning test (significance level 2.5%, non-inferiority margin 8.3%; primary endpoint), recurrent PU within 12 weeks, bleeding and time-to-event of PU (secondary

2017 EvidenceUpdates PubMed abstract

4. Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H.pylori-associated duodenal ulcer. (Full text)

Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H.pylori-associated duodenal ulcer. To conduct a systematic evaluation of the efficacy of lansoprazole and omeprazole for the treatment of Helicobacter pylori-associated duodenal ulcer.Online databases, including CHKD, VIP, China Info, the National Digital Library of China, Google Scholar, PubMed, Lippincott Williams & Wilkins, and Wiley Online Library were searched for related studies. The quality of the studies (...) was evaluated in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, and relevant information was extracted from them. The studies were subjected to meta-analysis using RevMan5.3 software, and qualitative analysis was performed for studies, in which the data could not be merged.A total of nine randomized controlled trials (RCTs) were included, all of which presented the possibility of bias. Meta-analysis showed no significant differences between patients treated with lansoprazole

2016 International journal of physiology, pathophysiology and pharmacology PubMed abstract

5. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy (Abstract)

Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy To evaluate the efficacy and tolerability of replacing tetracycline with amoxicillin in bismuth quadruple therapy.Subjects who were infected with Helicobacter pylori and naïve to treatment were randomly (1:1) assigned to receive a 14-day modified bismuth quadruple therapy: lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg (elemental bismuth), twice a day

2015 EvidenceUpdates Controlled trial quality: uncertain

6. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. (Full text)

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. Asymptomatic gastroesophageal reflux (GER) is prevalent in children with asthma. Untreated GER has been postulated to be a cause of inadequate asthma control in children despite inhaled corticosteroid treatment, but it is not known whether treatment with proton pump inhibitors improves asthma control.To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER.The (...) Study of Acid Reflux in Children With Asthma, a randomized, masked, placebo-controlled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma control who were receiving inhaled corticosteroid treatment. Three hundred six participants enrolled from April 2007 to September 2010 at 19 US academic clinical centers were followed up for 24 weeks. A subgroup had an esophageal pH study before randomization.Participating children were randomly assigned to receive either

2012 JAMA Controlled trial quality: predicted high PubMed abstract

7. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. (Abstract)

Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Microscopic colitis (MC), comprising lymphocytic and collagenous colitis (LC, CC), causes chronic diarrhoea. Lansoprazole can cause MC. Likelihood criteria defining the causative relationship between drugs and MC have not been applied to lansoprazole, nor has lansoprazole-related-MC been characterized.To analyse a series of lansoprazole-related MC cases (...) , and characterize lansoprazole-related CC and LC.Cases were diagnosed over 23 months and causal relationship evaluated by established likelihood criteria. A systematic Medline search was conducted and publications analysed.Eight patients had lansoprazole-related MC. In all cases chronological and causality likelihood scores supported lansoprazole causative role. Discontinuation determined resolution without further treatment. Twenty-five cases of lansoprazole-related MC from 10 publications were grouped

2011 Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

8. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients (Abstract)

A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).Twelve-month, randomized, observer-blind, controlled trial.A university hospital and three city hospitals in Miyagi prefecture in Japan.One hundred patients with COPD (mean age (...) +/- SD 74.9 +/- 8.2) participated. They were all ex-smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.Frequency of common colds and COPD exacerbations.The number of exacerbations per person

2009 EvidenceUpdates Controlled trial quality: uncertain

9. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study

Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

10. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. (Abstract)

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. To compare the efficacy of esomeprazole, 20 mg once daily, vs. lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis.During the initial open healing phase, 1391 patients with endoscopically verified reflux oesophagitis and a history of heartburn, with or without acid regurgitation, received esomeprazole 40 mg for 4-8 weeks. Patients (...) who were healed (identified by endoscopy at 4 or 8 weeks) and symptom free were then randomized to receive 6 months of treatment with esomeprazole, 20 mg once daily, or lansoprazole, 15 mg once daily.Esomeprazole, 20 mg once daily, maintained a significantly higher proportion of patients in remission than lansoprazole, 15 mg once daily, over 6 months [83% (95% CI, 80-86%) of esomeprazole recipients compared with 74% (95% CI, 70-78%) of lansoprazole recipients; P < 0.0001; life table estimates

2003 Alimentary pharmacology & therapeutics Controlled trial quality: uncertain

11. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. (Full text)

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain.We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H (...) . pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications.During a median follow-up of 12 months, 9 of the 61 patients in the placebo group (14.8 percent), as compared with 1 of the 62 patients in the lansoprazole group (1.6 percent), had a recurrence of ulcer complications (adjusted hazard ratio, 9.6; 95 percent

2002 NEJM Controlled trial quality: predicted high PubMed abstract

12. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. (Full text)

Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Omeprazole and lansoprazole are used to treat erosive oesophagitis in the respective daily doses of 20 and 30 mg.To investigate, by meta-analysis, whether treatment with lansoprazole 30 mg increases erosive oesophagitis healing rates over omeprazole 20 mg.We searched for randomized, double-blind trials comparing omeprazole 20 mg and lansoprazole 30 mg (...) in endoscopically diagnosed erosive oesophagitis. After assessing for homogeneity, non-heterogeneous trials were combined and pooled healing rates derived. We calculated the relative benefit increase, absolute benefit increase and number needed to treat.Six trials without significant heterogeneity met predetermined inclusion criteria. By per protocol analysis, pooled healing rates for omeprazole 20 mg and lansoprazole 30 mg were, respectively, 74.7% and 77.7% after 4 weeks and 87.0% and 88.7% after 8 weeks

2001 Alimentary pharmacology & therapeutics PubMed abstract

13. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. (Abstract)

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD).On the basis of the results of randomized (...) of acute therapy was healing rate, and the primary outcome for studies of maintenance therapy was relapse rate.Fifty-three studies were identified, of which 38 involved acute therapy (12 excluded) and 15 maintenance therapy. None of the studies of pantoprazole met the inclusion criteria for maintenance therapy. The 8-week overall healing rate ratios in the comparison of newer PPIs with omeprazole 20 mg/d were as follows: lansoprazole 30 mg/d, 1.02 (95% CI, 0.98-1.06): rabeprazole 20 mg/d, 0.93 (95% CI

2001 Clinical therapeutics

14. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

2001 DARE.

15. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. (Abstract)

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. The combination of lansoprazole with antibiotics either as double or triple therapy has demonstrated an H. pylori eradication rate of between 80 and 90%. With the aim of providing a complete revision of the results of these clinical studies and a quantification of the efficacy of lansoprazole in eradicating H. pylori and healing peptic ulcers, we have undertaken a meta-analysis of all the controlled studies published (...) in the literature.This meta-analysis reviewed all randomized, controlled clinical trials published as full text articles in English between 1993 and 1996 that reported the efficacy of lansoprazole treatment as monotherapy or in combination with antibiotics in the treatment of peptic ulcer and in eradicating H. pylori. Articles were identified from the literature, which included both manual and computerized research (MEDLINE) and references provided by articles in this area. In order to compare the efficacy of triple

1998 Helicobacter

16. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, De Luca L Authors' objectives To assess the efficacy of lansoprazole in eradicating Helicobacter pylori and healing peptic ulcers. Searching The authors searched MEDLINE and also scanned (...) the bibliographies of articles for additional relevant studies (search terms not stated). Only full-text published articles (1993 to 1996) were included although five published abstracts were included for the triple- therapy comparison of lansoprazole versus another proton pump inhibitor (PPI). Only English language studies were included. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs). Specific interventions included in the review Comparisons of: 1

1998 DARE.

17. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. (Abstract)

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. To compare the gastric ulcer healing rates of lansoprazole with histamine2-receptor antagonists (H2RAs) (ranitidine, famotidine, cimetidine, and roxatidine), a meta-analysis was performed using data from five published and eight unpublished randomized controlled trials. Analyses were performed using (1) both evaluable patients (n = 1527) and all randomized patients (n = 1655) (assuming (...) that patients lost to follow-up were treatment failures); (2) all studies and a subset of studies that received high methodologic quality scores; and (3) fixed-effects, random-effects, and Bayesian statistical models. In all cases, lansoprazole was associated with a significantly higher rate of endoscopic healing at both 4 and 8 weeks compared with the H2RAs. When the most conservative Bayesian statistical model and intent-to-treat analysis were used, lansoprazole was associated with a 33% higher healing

1997 Clinical therapeutics

18. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Tunis S R, Sheinhait I A, Schmid C H, Bishop D J, Ross S D Authors' objectives To compare the gastric ulcer healing rates of lansoprazole with histamine2-receptor antagonists (H2RAs). Searching (...) MEDLINE (1966 - 16 January 1996) including all languages, using the subject heading 'stomach ulcer' and text terms 'lansoprazole', 'lanzor', 'ogast', 'takepron', 'Prevacid', 'AG-1749', and 'EN-123065'. In addition, Current Contents was searched weekly, and bibliographies were handsearched. Unpublished trials were obtained from the drug's manufacturer. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing lansoprazole with a H2RA, recruiting

1997 DARE.

19. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview.

Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Manzionna G, Pace F, Bianchi Porro G Authors' objectives To re-evaluate the short- and long-term data regarding the treatment (...) of reflux oesophagitis with the newly developed proton-pump inhibitor lansoprazole, compared with other acid suppressant drugs. Searching The literature was searched both manually and electronically (MEDLINE). Only articles published in the English language between 1991 and 1996 were considered. Study selection Study designs of evaluations included in the review Randomised, controlled clinical studies were included. Specific interventions included in the review Lansoprazole (15, 30 or 60 mg/day

1997 DARE.

20. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. (Abstract)

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments.All randomized clinical trials in which lansoprazole was used to treat patients with duodenal ulceration were reviewed. The meta-analysis included a quality assessment for each (...) trial. The main criterion chosen for the meta-analysis was the endoscopic healing rate at 4 weeks; other criteria were the healing rate at 2 weeks and the absence of pain at 2 and 4 weeks. Statistical methods used were the Der Simonian and Laird method and the method of Peto et al. A sensitivity analysis was performed according to the H2 blocker type (famotidine or ranitidine). Odds ratios against histamine-receptor blockers were used to compare lansoprazole indirectly with omeprazole and other

1995 European journal of gastroenterology & hepatology